Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

5,167 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Systematic review of the incidence and prevalence of genital warts.
Patel H, Wagner M, Singhal P, Kothari S. Patel H, et al. BMC Infect Dis. 2013 Jan 25;13:39. doi: 10.1186/1471-2334-13-39. BMC Infect Dis. 2013. PMID: 23347441 Free PMC article. Review.
Clinical and economic consequences of vancomycin and fidaxomicin for the treatment of Clostridium difficile infection in Canada.
Wagner M, Lavoie L, Goetghebeur M. Wagner M, et al. Can J Infect Dis Med Microbiol. 2014 Mar;25(2):87-94. doi: 10.1155/2014/793532. Can J Infect Dis Med Microbiol. 2014. PMID: 24855476 Free PMC article.
Evidence and Value: Impact on DEcisionMaking--the EVIDEM framework and potential applications.
Goetghebeur MM, Wagner M, Khoury H, Levitt RJ, Erickson LJ, Rindress D. Goetghebeur MM, et al. BMC Health Serv Res. 2008 Dec 22;8:270. doi: 10.1186/1472-6963-8-270. BMC Health Serv Res. 2008. PMID: 19102752 Free PMC article. Review.
Appraising the holistic value of Lenvatinib for radio-iodine refractory differentiated thyroid cancer: A multi-country study applying pragmatic MCDA.
Wagner M, Khoury H, Bennetts L, Berto P, Ehreth J, Badia X, Goetghebeur M. Wagner M, et al. BMC Cancer. 2017 Apr 17;17(1):272. doi: 10.1186/s12885-017-3258-9. BMC Cancer. 2017. PMID: 28412971 Free PMC article.
Can the EVIDEM Framework Tackle Issues Raised by Evaluating Treatments for Rare Diseases: Analysis of Issues and Policies, and Context-Specific Adaptation.
Wagner M, Khoury H, Willet J, Rindress D, Goetghebeur M. Wagner M, et al. Pharmacoeconomics. 2016 Mar;34(3):285-301. doi: 10.1007/s40273-015-0340-5. Pharmacoeconomics. 2016. PMID: 26547306 Free PMC article.
Bridging health technology assessment (HTA) with multicriteria decision analyses (MCDA): field testing of the EVIDEM framework for coverage decisions by a public payer in Canada.
Tony M, Wagner M, Khoury H, Rindress D, Papastavros T, Oh P, Goetghebeur MM. Tony M, et al. BMC Health Serv Res. 2011 Nov 30;11:329. doi: 10.1186/1472-6963-11-329. BMC Health Serv Res. 2011. PMID: 22129247 Free PMC article.
From efficacy to equity: Literature review of decision criteria for resource allocation and healthcare decisionmaking.
Guindo LA, Wagner M, Baltussen R, Rindress D, van Til J, Kind P, Goetghebeur MM. Guindo LA, et al. Cost Eff Resour Alloc. 2012 Jul 18;10(1):9. doi: 10.1186/1478-7547-10-9. Cost Eff Resour Alloc. 2012. PMID: 22808944 Free PMC article.
Authors' Reply to Gandjour: "Can the EVIDEM Framework Tackle Issues Raised by Evaluating Treatments for Rare Diseases: Analysis of Issues and Policies, and Context-Specific Adaptation".
Wagner M, Goetghebeur M. Wagner M, et al. Pharmacoeconomics. 2017 May;35(5):605-606. doi: 10.1007/s40273-017-0498-0. Pharmacoeconomics. 2017. PMID: 28324439 No abstract available.
5,167 results
Jump to page
Feedback